SOURCES SOUGHT
A -- RNA Sequencing
- Notice Date
- 5/25/2016
- Notice Type
- Sources Sought
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services - Rockville, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001, United States
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA_16-223-SOL-1167862
- Archive Date
- 6/16/2016
- Point of Contact
- Howard Nesmith, Phone: 870-543-7459
- E-Mail Address
-
howard.nesmith@fda.hhs.gov
(howard.nesmith@fda.hhs.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- THIS IS A SOURCES SOUGHT ANNOUNCEMENT, A MARKET SURVEY FOR WRITTEN INFORMATION ONLY. THIS IS NOT A SOLICITATION ANNOUNCEMENT FOR PROPOSALS AND NO CONTRACT WILL BE AWARDED FROM THIS ANNOUNCEMENT. NO REIMBURSEMENT WILL BE MADE FOR ANY COSTS ASSOCIATED WITH PROVIDING INFORMATION IN RESPONSE TO THIS ANNOUNCEMENT OR ANY FOLLOW-UP INFORMATION REQUESTS. NO TELEPHONE CALLS WILL BE ACCEPTED REQUESTING AN RFQ PACKAGE OR SOLICITATION. THERE IS NO RFQ PACKAGE OR SOLICITATION. IN ORDER TO PROTECT THE PROCUREMENT INTEGRITY OF ANY FUTURE PROCUREMENT, IF ANY, THAT MAY ARISE FROM THIS ANNOUNCEMENT, INFORMATION REGARDING THE TECHNICAL POINT OF CONTACT WILL NOT BE GIVEN AND NO APPOINTMENTS FOR PRESENTATIONS WILL BE MADE. The U.S. Food and Drug Administration (FDA), Office of Acquisitions and Grants Services (OAGS) has issued this sources sought announcement on behalf of the Center for Biologics Evaluation and Research (CBER), who requires RNA Sequencing of B. pertussis infected tissue to evaluate bacterial and host gene expression. If your firm is considered a small business source under North American Industry Classification System (NAICS) 541380 - Testing Laboratories; with a Small Business Size standards $15 million, and believe your firm would be able to provide the FDA with the RNA Sequencing as described below, please submit an email to howard.nesmith@fda.hhs.gov. The vendor shall include information about the company which demonstrates they can meet all of the minimum requirements. Background: Pertussis is an acute, highly contagious; potentially life threatening respiratory disease caused by the Gram-negative bacterium Bordetella pertussis. Pertussis is the most common disease-preventable disease in the United States. The underlying factors leading to the failure of public health measures to control pertussis disease using currently licensed vaccines are poorly understood. A more complete understanding of this disease and of the mechanisms of vaccine-mediated protection is a critical public health need. Studies conducted by CBER have demonstrated the validity of the baboon species as a candidate translational model for Pertussis research. CBER has conducted studies of vaccinated and unvaccinated baboons and collected tissue samples from the airways of animals in order to evaluate gene expression in both the bacterial cells and the host tissues during B. pertussis infection of the host. The isolation of intact, highly purified bacterial RNA from NHP lung tissue in sufficient quantity and sufficient quality for deep sequencing is very technologically challenging. Therefore in a previous study conducted by Tufts University Core Facility (TUCF) Genomics Core, complex protocols were developed that allowed for sequencing of both bacterial and host RNA from tissue and blood samples pertussis-infected baboons. The previous studies provided proof of concept and raised important scientific questions. Statement of Need: CBER requires a contractor to isolate bacterial and host RNA from baboon lung tissue samples, generate bacterial and host RNA libraries from each sample, and perform deep sequencing of each library. Technical Requirements: - The Contractor shall have experience preparing B. pertussis RNA libraries from non-human primate tissue samples in order to be entrusted with the FDA supplied samples, for the B. pertussis-infected baboon samples are irreplaceable. - The Contractor shall demonstrate ability to prepare bacterial RNA libraries from lung tissue derived from B. pertussis infected non-human primates suitable for deep RNA sequencing - The Contractor shall demonstrate ability to prepare mammalian RNA libraries from lung tissue derived from non-human primates suitable for deep RNA sequencing - The Contractor shall demonstrate ability to prepare bacterial RNA libraries from plate- grown B. pertussis suitable for deep RNA sequencing - The Contractor shall demonstrate ability to prepare mammalian RNA libraries from blood samples derived from non-human primates suitable for deep RNA sequencing - The Contractor shall demonstrate ability to perform Illumina HiSeq sequencing of bacterial and mammalian RNA to achieve a minimum of 250 million reads per sample - The Contractor shall prepare bacterial gene expression, BAL vs. NPW - The Contractor shall isolate bacterial RNA from 6 baboon bronchoalveolar lavage (BAL) samples and 6 baboon nasopharyngeal wash (NPW) samples, preparation of 12 RNA libraries, and sequencing to achieve a minimum of 250 million reads per sample - The Contractor shall prepare bacterial gene expression, vaccinated vs. unvaccinated Isolation of bacterial RNA from 7 baboon bronchoalveolar lavage (BAL) samples, preparation of 7 RNA libraries, and sequencing to achieve a minimum of 250 million reads per sample - The Contractor shall prepare host responses by isolation of eukaryotic RNA from 20 baboon lung tissue samples, preparation of 20 RNA libraries with sequencing to achieve a minimum of 50 million reads per sample - The Contractor shall prepare bacterial gene expression in lung tissue by isolation of bacterial RNA from 5 baboon lung tissue samples, preparation of 5 RNA libraries with sequencing to achieve a minimum of 250 million reads per sample - The Contractor shall prepare host responses to vaccination and infection by isolation of bacterial RNA from 172 baboon blood samples, preparation of 172 RNA libraries with sequencing to achieve a minimum of 50 million reads per sample FOB Destination: U.S. Food and Drug Administration Center for Biologics Evaluation and Research 10903 New Hampshire Avenue Silver Spring, MD 20993 Responses to this sources sought shall unequivocally demonstrate that the respondent is regularly engaged in RNA sequencing. Though the target audience is small business or small businesses capable of providing service from another small business, all interested parties may respond. At a minimum, responses shall include the following: - Business name and bio, DUNS number, business address, business website, business size status (i.e., SB, VOSB, SDVOSB, HUBZone SB, SDB, WOSB, LB), point of contact name, mailing address (if different from business address), phone number and email address. Provide this same information again if responding to provide a service offered by another firm. - Past Performance information shall include date of services, description, dollar value, client name, client address, client contact name, client point of contact mailing address (if different from that provided for client), client point of contact phone number, client point of contact email address, and name of company (to include DUNS number and size status) if not the respondent. - Descriptive literature, brochures, marketing material, etc. detailing the nature of services the responding firm is regularly engaged in providing. - If applicable, identification of the firm's GSA Schedule contract(s) by Schedule number and SINs that are applicable to this potential requirement are also requested. If a large business, provide if subcontracting opportunities exist for small business concerns. The Government is not responsible for locating or securing any information, not identified in the response. Interested Contractors must respond with capability statements in person, by e-mail, fax, mail or other delivery method before 1:00 pm (Central Standard Time - Local Prevailing Time in Jefferson, Arkansas) on June 1, 2016 to howard.nesmith@fda.hhs.gov, Fax (870) 543-7990, or mail to the U. S. Food and Drug Administration, OO/OFBA/OAGS/DAP, Attention of Howard Nesmith, 3900 NCTR Road, Building 50, Room 424, Jefferson, AR 72079-9502 and Reference: FDA_16-223-SOL-1167862. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre‐solicitation synopsis and solicitation may be published in FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non‐proprietary technical information in any resultant solicitation(s). Additional Notes: If the stated requirements appear restrictive, please submit comments detailing the concern. Though this is not a request for quote, informational pricing for the service would be helpful.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA_16-223-SOL-1167862/listing.html)
- Place of Performance
- Address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States
- Zip Code: 20993
- Zip Code: 20993
- Record
- SN04128147-W 20160527/160525234203-952c910099e923f02c577d7aeaee2e21 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |